As of September 30, 2025, the Company had $104.0 million of cash, cash equivalents, and investment on hand. Since the end of the third quarter ended September 30, 2025, the Company raised a total of $73.8 million in net proceeds from the issuance of 4,976,510 shares of common stock from an underwritten public offering and ATM sales. The Company believes it has sufficient cash to fund operations into 2028 based on current operating plans and assumptions regarding clinical timelines and planned expenditures.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals reports Q3 EPS ($1.90), consensus ($1.71)
- CRBP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corbus Pharmaceuticals management to meet virtually with B. Riley
- Corbus Pharmaceuticals Announces $70.5M Public Offering
- Corbus Pharmaceuticals 4.744M share Spot Secondary priced at $13.00